Astria Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jill C. Milne
- Full Time Employees
- 78
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 High Street Boston MA United States of America 02110
- IPO Date
- Jun 25, 2015
- CIK
- 0001454789
- Website
- astriatx.com
- Similar Companies
- Business
- Astria Therapeutics, Inc. Astria Therapeutics, Inc. (ATXS), a biopharmaceutical company, discovers, develops and commercializes therapeutics for allergic and immunologic diseases, including hereditary angioedema and atopic dermatitis; its lead product candidate, navenibart, comprises a monoclonal antibody inhibitor of plasma kallikrein in Phase 3 clinical trials for hereditary angioedema prophylaxis with every-three- and every-six-month subcutaneous dosing regimens; it also advances STAR-0310, a monoclonal antibody OX40 antagonist in clinical development for atopic dermatitis targeting patients unresponsive to existing therapies such as Dupixent. The company operates primarily in the United States, serving patients with rare and niche allergic conditions through its pipeline of differentiated biologics designed for superior efficacy, safety, tolerability and low treatment burden. Founded in 2008 and headquartered in Boston, Massachusetts, Astria Therapeutics, Inc. formerly operated as Catabasis Pharmaceuticals, Inc., changing its name in September 2021; it recently announced a definitive merger agreement with BioCryst Pharmaceuticals, Inc. on October 14, 2025, under which Astria will become a wholly owned subsidiary in an approximately $700 million all-cash-and-stock transaction valuing shares at $13 apiece, bolstering BioCryst's hereditary angioedema portfolio alongside navenibart's ongoing pivotal trials.
Astria Stockholders Vote to Approve Acquisition by BioCryst
Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS)
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
BioCryst to buy Astria Therapeutics in $700 million deal